Barchart.com
[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.

Morphosys Ag ADR (MOR)

Morphosys Ag ADR (MOR)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Help
Go To:
MorphoSys AG Reports First Quarter 2023 Financial Results Business Wire - Wed May 3, 2023

MorphoSys AG (FSE: MOR; NASDAQ: MOR) reports results for the first quarter of 2023 .

MOR : 18.96 (+2.43%)
MorphoSys and Incyte Announce Five-Year Results of L-MIND Study Showed Prolonged, Durable Responses in Relapsed or Refractory DLBCL Patients Treated with Monjuvi® (tafasitamab-cxix) Business Wire - Sun Apr 16, 2023

MorphoSys U.S. Inc., a fully owned subsidiary of MorphoSys AG (FSE: MOR; NASDAQ: MOR), and Incyte (Nasdaq: INCY) today announced final five-year follow-up data from the Phase 2 L-MIND study showing that...

MOR : 18.96 (+2.43%)
INCY : 119.56 (-0.80%)
Why Shares of MorphoSys Are Up Wednesday Motley Fool - Wed Apr 5, 2023

The company's phase 3 trial for a lead therapy is ahead of schedule.

MOR : 18.96 (+2.43%)
MorphoSys AG Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update Business Wire - Wed Mar 15, 2023

MorphoSys AG (FSE: MOR; NASDAQ: MOR) reports results for the fourth quarter and the full year 2022.

MOR : 18.96 (+2.43%)
MorphoSys AG Reports First Nine Months and Third Quarter 2022 Financial Results Business Wire - Wed Nov 16, 2022

Conference call and webcast (in English) tomorrow, November 17, 2022, at 2:00pm CET (1pm GMT/8:00am ET)

MOR : 18.96 (+2.43%)
CARsgen Appoints Dr. Sylvie Peltier as Senior Vice President of Global Regulatory Affairs PR Newswire - Mon Oct 31, 2022

/PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of...

MOR : 18.96 (+2.43%)
TEVA : 36.64 (+0.33%)
MorphoSys Reports Preliminary Q2 2022 Monjuvi U.S. Sales and Updates Financial Guidance for 2022 ACCESS Newswire - Tue Jul 26, 2022

PLANEGG/MUNICH, GERMANY / ACCESSWIRE / July 26, 2022 / MorphoSys AG (FSE:MOR)(NASDAQ:MOR) today reported preliminary U.S. net product sales of Monjuvi® (tafasitamab-cxix) for the second quarter 2022 and...

MOR : 18.96 (+2.43%)
MPSYF : 73.2700 (+2.10%)
MorphoSys AG Reports Preliminary Q2 2022 Monjuvi U.S. Sales and Updates Financial Guidance for 2022 ACCESS Newswire - Tue Jul 26, 2022

Publication of an inside information according to Article 17 para. 1 of the Regulation (EU) No. 596/2014

MOR : 18.96 (+2.43%)
MPSYF : 73.2700 (+2.10%)
MorphoSys AG Reports Outcome of Annual General Meeting 2022 ACCESS Newswire - Wed May 18, 2022

PLANEGG/MUNICH, GERMANY / ACCESSWIRE / May 18, 2022 / MorphoSys AG (FSE:MOR); (NASDAQ:MOR) announced today that its shareholders approved all resolutions proposed by the Company´s Management and Supervisory...

MOR : 18.96 (+2.43%)
Invitation to MorphoSys' First Quarter 2022 Financial Results Conference Call on May 5, 2022 ACCESS Newswire - Thu Apr 28, 2022

Our newswire features a comprehensive, flat-fee Press Release service. Generate quality engagement with real-time analytics to improve visibility and expand your influence.

MOR : 18.96 (+2.43%)

Barchart Exclusives

Coreweave Stock Is Back in Rally Mode. How CRWV Can Reclaim Its $153.20 High. Barchart - 50 minutes ago
CoreWeave delivered an exceptional second quarter, with revenue reaching $2.6 billion, up 112% year-over-year and 24% sequentially. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.